Drug Repositioning for Neurodegenerative Diseases

Drug Repositioning for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repositioning for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Use</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Mucolytic</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Dementia</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Epilepsy/BD</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Bipolar</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Hypertension</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Stroke</td>
</tr>
<tr>
<td class="label">Zonisamide</td>
<td>Epilepsy</td>
</tr>
</table>

Drug Repositioning For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Drug Repositioning for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repositioning for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Use</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Mucolytic</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Dementia</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Epilepsy/BD</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Bipolar</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Hypertension</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Stroke</td>
</tr>
<tr>
<td class="label">Zonisamide</td>
<td>Epilepsy</td>
</tr>
</table>

Drug Repositioning For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Drug repositioning (also known as drug repurposing) is a strategic approach to identifying new therapeutic applications for existing drugs that were originally developed for different conditions. This overview explains the drug repositioning methodology, its advantages over traditional drug development, and its growing importance in neurodegenerative disease therapy development.

In the context of neurodegenerative diseases, drug repositioning offers a faster and more cost-effective path to clinical translation compared to developing novel compounds from scratch. Many drugs with established safety profiles are being investigated for neuroprotective effects in Alzheimer's disease, Parkinson's disease, ALS, and other conditions.

Overview

Drug repositioning (also called drug repurposing) is a strategic approach to identify existing FDA-approved drugs for new therapeutic applications in neurodegenerative diseases. This approach leverages known safety profiles, pharmacokinetics, and manufacturing processes to accelerate the development timeline and reduce costs compared to de novo drug development[@pushpakom2019].

The high failure rate and enormous costs associated with developing new drugs for neurodegenerative diseases have made repositioning an attractive strategy. By identifying existing drugs that may have disease-modifying effects in conditions like Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease, researchers can potentially bring new treatments to patients faster than traditional drug development pathways allow.

Rationale for Repositioning

Advantages Over De Novo Development

• Reduced development time: 3-12 years vs. 10-15 years for new drugs
• Lower development costs: Estimated $1-2 billion vs. $2-6 billion
• Established safety profiles: Extensive clinical safety data available
• Known pharmacokinetics: ADME properties already characterized
• Regulatory pathway: May qualify for 505(b)(2) approval pathway[@ashburn2004]

Challenges

• Patent considerations: May require new formulation or dosing patents
• Intellectual property: Original compound patents may limit exclusivity
• Mechanistic uncertainty: Understanding of new indications may be incomplete
• Dosing optimization: May require different dosing for new indications[@sleire2017]

Repositioned Drugs with Strong Evidence

Metformin

Original indication: Type 2 diabetes

Neurodegenerative applications:

• Alzheimer's disease: AMPK activation reduces [mTOR](/entities/mtor) signaling, enhances [autophagy](/entities/autophagy), improves insulin sensitivity in brain[@mattson2010]
• Parkinson's disease: May reduce neuroinflammation, improve mitochondrial function[@rotermund2014]
• ALS: Metabolic effects may support motor neuron function[@woo2015]

GLP-1 Receptor Agonists

Original indication: Type 2 diabetes

Neurodegenerative applications:

• Parkinson's disease: Neuroprotective effects via PI3K/Akt, AMPK, and [NF-κB](/entities/nf-kb) pathways[@athauda2016]
• Alzheimer's disease: Reduces neuroinflammation, improves synaptic function[@holscher2014]
• ALS: May protect motor [neurons](/entities/neurons) through anti-apoptotic mechanisms[@gulak2020]

Statins

Original indication: Hypercholesterolemia

Neurodegenerative applications:

• Alzheimer's disease: May reduce [Aβ](/proteins/amyloid-beta) production, anti-inflammatory effects[@zhou2019]
• Parkinson's disease: Potential neuroprotection through multiple mechanisms[@wang2017]
• ALS: Cholesterol-independent effects may benefit motor neurons[@saenger2015]

Minocycline

Original indication: Antibacterial

Neurodegenerative applications:

• ALS: Anti-apoptotic, anti-inflammatory effects[@kriz2002]
• Parkinson's disease: May protect dopaminergic neurons[@du2015]
• Huntington's disease: May reduce microglial activation[@chen2000]

Lithium

Original indication: Bipolar disorder

Neurodegenerative applications:

• Alzheimer's disease: May reduce [tau](/proteins/tau) phosphorylation, enhance autophagy[@noble2005]
• ALS: May slow disease progression through neuroprotective mechanisms[@fornai2008]
• Huntington's disease: May provide neuroprotection[@chiu2010]

Drugs with Moderate Evidence

High-Throughput Screening Approaches

Bioinformatics-Based Repositioning

• Gene expression profiling: Comparing disease signatures with drug signatures[@iorio2010]
• Protein interaction networks: Identifying drug-protein interactions in disease networks[@menche2015]
• Electronic health records: Mining for unexpected therapeutic effects[@wu2018]

Model-Based Approaches

• C. elegans models: High-throughput screening in simple nervous system models[@odonnell2020]
• iPSC models: Patient-derived neurons for drug testing[@sterneckert2014]
• Machine learning: Predicting drug-disease relationships[@jarada2020]

Clinical Development Considerations

Trial Design

• Adaptive trials: Efficient dose-finding and endpoint selection
• Basket trials: Single trial testing drug across multiple indications
• Platform trials: Continuous evaluation of multiple repositioning candidates[@woodcock2017]

Regulatory Pathways

• 505(b)(2) pathway: Leverages existing safety data
• Orphan drug designation: For rare neurodegenerative diseases
• Fast track/breakthrough therapy: For promising candidates[@us2019]

Challenges and Limitations

• Dose selection: Optimal dose for CNS indications may differ from original
• Brain penetration: Some repositioned drugs have poor [BBB](/entities/blood-brain-barrier) penetration
• Mechanistic understanding: May lack clear understanding of therapeutic mechanism
• Long-term effects: Safety data from short-term use may not translate to chronic treatment[@mercan2021]

See Also

• [GLP-1 Receptor Agonists for Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
• [NAD+ Precursor Therapy for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration)
• [Molecular Chaperone Therapy](/therapeutics/molecular-chaperone-therapy)
• [Antioxidant Therapy for Neurodegeneration](/therapeutics/antioxidant-therapy-neurodegeneration)

External Links

• [NCATS Repurposing Database](https://ncats.nih.gov/)
• [DrugBank Database](https://go.drugbank.com/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Drug Repositioning For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References